Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 1998

View Archived Issues

AE-0047: a calcium channel blocker with multiple indications

Company Profile: Aquila Biopharmaceuticals

IDEC-Y2B8/rituximab combination enters phase III

Rizatriptan approved in The Netherlands

AIT-082 enters multidose study

Noven and Novartis to collaborate on Vivelle

Antimigraine agents with reduced liability for side effects developed at MS&D

Orally active thrombin inhibitors prepared at C&C

Schering AG reports pure antiestrogens

Beta-lactams with dual beta-lactamase-inhibitory/antibacterial activity from Roche

Fujisawa develops new inhibitors of NO production

Medivir studies new anticancer sterols

Canadian approval obtained for Mirapex

Taxotere approved in China

Binding and functional studies with YM-087 in cells expressing human AVP receptors

Novel 5-HT2A receptor antagonist from medicinal plant: gamma-mangostin

Beneficial effects of FK-506 in animal model of rheumatoid arthritis

Preclinical studies support development of G-3139 as chemosensitizer

Connetics' NDA for betamethasone mousse accepted by FDA

Development candidate selected by Fujisawa from ACAT inhibitor series

Milestone reached in Genome Therapeutics/Schering-Plough alliance

Improved treatment outlook for children with leukemia?

UroGenesys licenses prostate cancer gene for diagnostic and therapeutic development

AutoImmune will conduct pivotal study of Colloral

ProLease formulation of erythropoietin covered by U.S. patent

Patent coverage for ProLease interferon

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...